New features include an injection port for small volume additions, a sub-surface fluid port for either addition or removal, and an extra port for the insertion of a third probe. The enhanced version replaces the first-generation Mobius launched in 2009.
Andrew Bulpin, head of services and solutions, Process Solutions, at EMD Millipore, said the enhanced operational and process monitoring capabilities in the new version would enable operations such as perfusion and monitoring of additional cell culture parameters such as carbon dioxide, viable cell density or optical density.
Designed to replace traditional glass benchtop bioreactors, the Mobius CellReady 3L Bioreactor has a standard stirred-tank format for use in development and optimisation of cell culture processes.
According to Millipore, by eliminating time-consuming steps associated with cleaning, assembly, and sterilisation, the Mobius CellReady 3L bioreactor significantly reduces the turnaround time typically associated with glass bioreactors.
Millipore upgrades Mobius CellReady Bioreactor
Offers increased operational flexibility and enhanced process monitoring
You may also like
Trending Articles
You may also like
Manufacturing
![SCHOTT Pharma launches EVERIC lyo & amber vials for light-sensitive ADCs]()
SCHOTT Pharma launches EVERIC lyo & amber vials for light-sensitive ADCs
Featuring the well-known EVERIC® lyo coating, EVERIC® lyo & amber is designed for lyophilised, light-sensitive antibody-drug-conjugates (ADCs). It offers reliable light protection at the primary packaging level, already during the fill-and-finish process. EVERIC amber is the first specialty vial for highly light-sensitive medications that simultaneously meets regulatory light transmission requirements in the EU, the U.S., and Japan
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
![Portable gas detection in the pharmaceutical sector]()
Portable gas detection in the pharmaceutical sector
Gas safety is a critical consideration in the pharmaceutical sector. Hazardous gases and airborne contaminants are common by-products of manufacturing processes … and employers must control worker exposure in accordance with relevant legislation and industry standards
Manufacturing
![New legal duties for QPs in decentralised manufacturing]()
New legal duties for QPs in decentralised manufacturing
In this clip, Dr. Peter Gough explains that QPs will be responsible for supervising decentralised activities, conducting regular audits, carrying out periodic on-site visits, confirming GMP compliance to regulatory authorities and notifying changes that may affect quality or safety
Manufacturing
![FDA escalates action against Dabur India over systemic data-integrity and cGMP failures]()
FDA escalates action against Dabur India over systemic data-integrity and cGMP failures
The US FDA has issued a warning letter to Dabur India following an inspection that identified falsified records, missing laboratory data, inadequate cleaning and process validation and weaknesses in quality-unit oversight, saying the company's response failed to address the systemic nature of the deficiencies
Manufacturing
![DNA Script and GE Healthcare awarded $26m ARPA-H funding to scale cell-free DNA bioproduction]()
DNA Script and GE Healthcare awarded $26m ARPA-H funding to scale cell-free DNA bioproduction
The pair will combine DNA Script's EDS technology with GE HealthCare's DNA scaling technology to create a faster, more flexible manufacturing process for cell-free DNA as the use of personalised and time-sensitive genetic medicines grows
